Inactive Instrument

Press Releases APTINYX

Equities

APTX

US03836N1037

Press Releases

Unlock all the news: Be the first to know and act before the market!

APTINYX INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	11/23/11	AQ
APTINYX INC. : Other Events, Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	05/23/05	AQ
APTINYX INC. : Termination of a Material Definitive Agreement (form 8-K)	25/23/25	AQ
APTINYX INC. : Change in Directors or Principal Officers (form 8-K)	19/23/19	AQ
APTINYX INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	31/23/31	AQ
APTINYX INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)	31/23/31	AQ
Aptinyx Reports on Fourth Quarter and Full Year 2022 Results and Highlights and Review of Strategic Alternatives	31/23/31	BU
Henry Gosebruch, Former AbbVie EVP and Chief Strategy Officer, Joins ACELYRIN, INC. Board of Directors	30/23/30	AQ
Aptinyx : Costs Associated with Exit/Disposal - Form 8-K	01/23/01	PU
APTINYX INC. : Costs Associated with Exit or Disposal Activities (form 8-K)	01/23/01	AQ
APTINYX INC. : Other Events, Financial Statements and Exhibits (form 8-K)	28/23/28	AQ
Aptinyx Reports Results from Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson's Disease and Dementia with Lewy Bodies and Provides Pipeline and Corporate Update	28/23/28	BU
Aptinyx to Present at the SVB Securities Global Biopharma Conference	31/23/31	BU
APTINYX INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	09/22/09	AQ
APTINYX INC. : Change in Directors or Principal Officers (form 8-K)	02/22/02	AQ
Preclinical Data from Aptinyx’s NMDA Receptor Modulators to be Presented at the 52nd Annual Meeting of the Society for Neuroscience	10/22/10	BU
APTINYX INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	09/22/09	AQ
APTINYX INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)	09/22/09	AQ
Aptinyx Reports Third Quarter 2022 Financial Results and Recent Highlights	09/22/09	BU
Clinical Evaluation of Aptinyx's NYX-783 for Treatment of Opioid Use Disorder to Be Funded by $5.6 Million NIH Grant	03/22/03	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases APTINYX

Equities

APTX

US03836N1037

Press Releases

Filters